The Timed Stocks Mega Bundle - The Exact Day and Time Ten Timed Stocks Soared The Massive Gains They Could Have Handed You PLUS Three Timed ...
←
→
Page content transcription
If your browser does not render page correctly, please read the page content below
SPECIA L REPORT
The Timed Stocks Mega Bundle
The Exact Day and Time Ten Timed Stocks Soared…
The Massive Gains They Could Have Handed You…
PLUS Three Timed Stocks on Jeff’s Watchlist
By Jeff Brown
A Bonne r & Pa rtners Pub lica tion
Special Report 2020
The Timed Stocks Mega Bundle
The Exact Day and Time 10 Timed Stocks Soared… The Massive Gains They
Could Have Handed You… PLUS Three Timed Stocks on Jeff’s Watchlist
By Jeff Brown, Chief Technology Analyst, Bonner & Partners
Today, the largest fortunes are
being made from tech stocks…
For instance, Amazon went public
on May 15, 1997. At the time, its
enterprise valuation was $438
million. It generated $147.8
million in revenue that year and
generated a mere $2.7 million in
free cash flow the following year.
In 2017, Amazon had its 20-year
anniversary as a public company.
Look at what happened over the
two decades that followed…
On a split-adjusted stock basis,
Amazon rose from $1.54 per
share to where it is trading today But something has changed over the past
around $1,904 per share. That is an incredible decade. Regular investors have been locked out
1,236 times your money, or a 123,536% return of the “next Amazons.” The best technology
on investment. In other words, a $10,000 investments are being reserved for Silicon Valley
investment in Amazon at its IPO would now be venture capitalists and connected insiders.
worth a staggering $12.36 million. Everyday investors are being left with the scraps.
The precise numbers might have changed by Five years ago, I embarked on a mission to
the time you read this research. But the point is change that. I wanted to give normal investors
the same. Amazon’s IPO was a great investment the chance to stake a claim in early stage tech
opportunity. companies on the verge of massive growth. And I
believe I’ve found it.
2
In this special research briefing, I’ll reveal a Few investors realize it, but there is a small
special subset of the technology market that can group of stocks that have a fixed “timer” on their
deliver large, fast gains for normal investors. And share price. These stocks fly under the radar
I’ll show you the special group of tech stocks that while the timer ticks down. Then, seemingly out
soar triple-digits in weeks or days. of nowhere, they can soar triple digits in a matter
of weeks, days, or even hours.
Timed Stocks
I call these “timed stocks.” And I’ve developed
Hello, my name is Jeff Brown. For nearly three a system to spot these fast-moving investments
decades, I worked at the executive level for some before they shoot higher.
of the world’s most important technology firms.
I’m talking about companies like Qualcomm, To illustrate how powerful this system is and to
NXP Semiconductors, and Juniper Networks. demonstrate why we call these timed stocks, I
want to walk you through 10 trades. I’ll give you
And as an active angel investor, I’ve put a brief overview of the company, and I’ll walk
my money into over 145 private technology you through each trade. You will quickly notice
companies. And by my own estimates, I’ve seen that these each follow a similar pattern.
returns as high as 25,000%.
Now, nine of these are trades we made during
These days, I use my technology and investing our backtests. And one of these is a 432% trade
expertise to help everyday investors stake a claim my readers were able to recently lock-in. That
in the most exciting technology companies on was our very first closed trade.
the planet. And recently, I had something of a
breakthrough.
3
1. bluebird bio (BLUE)
Founded: 1992
Headquarters: Cambridge, MA
Website: www.bluebirdbio.com
This is bluebird bio (BLUE). The company develops gene therapies for severe genetic and
rare diseases.
Looking at the chart above, we can see that the stock popped higher right after its IPO in
June 2013. BLUE gained nearly 40% in its first month of trading.
But the stock plummeted 50% from its post-IPO high as it neared its lock-up expiration
date. That’s what created our buy signal. We call this the “magic window.”
A lock-up expiration date is usually 180 days after the IPO. It is the date after which
early investors in the company, who held shares before the IPO, are actually able to
sell and take some profits. The investment community well understands this and often
sells large amounts of shares leading into the lock-up expiration because it expects
early investors will start selling their stocks upon the lock-up expiration date.
4
From there, the stock chopped back and forth for about six months until it started to gain
momentum. Then the first catalyst happened. Bluebird announced strong data from its
FDA trials, and the stock shot up 482%.
There was a small pullback before another catalyst rocketed the stock even higher.
The FDA designated bluebird’s top therapy as a “breakthrough therapy,” and the stock
exploded – ultimately hitting 1,008% gains. That was enough to turn every $5,000
investment into $55,400.
5
2. Esperion Therapeutics (ESPR)
Founded: 2008
Headquarters: Ann Arbor, MI
Website: www.esperion.com
Here is Esperion Therapeutics (ESPR). This company specializes in developing oral
therapies for lipid management.
Esperion Therapeutics went public in June 2013 and traded 32% higher in the first four
months. Then the stock dropped 41% in less than two months. That’s when we got our buy
signal.
From there, the stock traded sideways for nearly a year until we got our first catalyst.
Investors would have had to be patient with this one… But the gain was worth the wait.
Esperion’s breakthrough therapy to lower cholesterol was proven to be effective in the
Phase 2 clinical trial… And the stock took off. ESPR ultimately soared 939% from our
entry, turning every $5,000 invested into $51,950.
6
3. MyoKardia (MYOK)
Founded: 2012
Headquarters: South San Francisco, CA
Website: https://myokardia.gcs-web.com
This is MyoKardia (MYOK). MyoKardia focuses on therapies to treat cardiovascular
disease.
The company went public in October 2015 and shot up 60% right out of the gate. But
then the stock plummeted 58%, falling well below the IPO price. That’s when our system
generated a buy signal.
From there, the stock enjoyed a nice run for over a year until the first catalyst hit.
MyoKardia’s breakthrough therapy was proven to be effective in the Phase 2 clinical trial
and the stock rocketed 884% higher. That would have turned every $5,000 investment
into $49,200.
7
4. Regenxbio (RGNX)
Founded: 2009
Headquarters: Rockville, MD
Website: www.regenxbio.com
Here is Regenxbio (RGNX). This is a gene therapy company targeting metabolic,
neurodegenerative, and retinal diseases.
Regenxbio went public in September 2015 and shot up 38% on the first day of trading. But
then the stock dropped 61%, falling well below the IPO price. That’s when we got our buy
signal.
From there, we only had to wait about a month and a half before the first catalyst hit.
Regenexbio presented preclinical data showing that its approach was effective in treating
neurodegenerative diseases, and the stock soared 768% higher. That would have turned
every $5,000 investment into $43,400.
8
5. Clovis Oncology (CLVS)
Founded: 2009
Headquarters: Boulder, CO
Website: https://clovisoncology.com
This is Clovis Oncology (CLVS). Clovis is working on precision medicine therapies for
certain types of cancer.
The company went public in November 2011. The stock fell 34% in the first month of
trading, creating a fantastic buying opportunity.
From there, the stock traded sideways for a little over a year before the first catalyst hit.
When the Phase 1/2 clinical trials showed that Clovis Oncology’s approach to treating lung
cancer worked, the stock took off.
Ultimately, CLVS hit peak gains of 585% above our entry point. That would have turned
every $5,000 investment into $34,250.
9
6. AnaptysBio (ANAB)
Founded: 2005
Headquarters: San Diego, CA
Website: www.anaptysbio.com
Here is AnaptysBio (ANAB). This company focuses on developing therapies for unmet
needs in inflammation and immuno-oncology.
AnaptysBio went public in January 2017, and it jumped nearly 17% on the first day of
trading. Then it ran up another 92% by the end of March.
But then the stock plunged 28% over the next four and a half months, falling back to levels
it hadn’t seen since its first month of trading. That’s what created our buying opportunity.
From there, we only had to wait two months for our first catalyst to hit. AnaptysBio
presented Phase 2 trial data showing that its therapeutic antibody approach to severe
atopic dermatitis was effective.
That sent the stock soaring, and it ultimately hit peak gains of 566% above our entry point.
That would have turned every $5,000 investment into $33,300.
107. Reata Pharmaceuticals (RETA)
Founded: 2002
Headquarters: Irving, TX
Website: www.reatapharma.com
Here is Reata Pharmaceuticals (RETA). Reata develops therapies to address serious and
life-threatening diseases by targeting molecular pathways.
The company went public in May 2016 and shot up 127% in its first month as a publicly
traded company. But then the stock fell 40%, creating a fantastic buy window.
From there, the stock traded sideways for a little over a year until the first catalyst hit.
Reata presented positive Phase 2 trial data showing that its approach to treating kidney
disease was effective.
That sent the stock soaring, and it ultimately hit peak gains of 478% above our entry point.
That would have turned every $5,000 investment into $28,900.
118. G1 Therapeutics (GTHX)
Founded: 2008
Headquarters: Durham, NC
Website: www.g1therapeutics.com
This is G1 Therapeutics (GTHX). G1 is engaged in developing small molecule therapies to
treat cancer.
The company went public in May 2017 and ran up 28% in its first month of trading. But
then the stock plunged 35%, triggering our buy signal.
From there, the stock traded steadily higher for six months until the first catalyst hit.
That’s when G1 Therapeutics announced in an earnings report that it would present Phase
2 trial data for its lead therapy the following month.
That sent the stock rocketing higher, and it ultimately hit peak gains of 442% above our
buy window. That would have turned every $5,000 investment into $27,100.
129. Synthorx (THOR)
Founded: 2014
Headquarters: La Jolla, CA
Website: https://synthorx.com
Here is Synthorx (THOR). Synthorx is a genetic medicine company developing therapies
for cancer and autoimmune diseases. And this happens to be the very first trade my
readers closed.
Here’s what the early stage trade looked like…
Synthorx went public in December 2018 and ran up 111% in its first two months of trading.
But then the stock plunged 45% over the next eight months, triggering our buy signal.
True to form, our system identified the opportunity and generated a buy alert at the
absolute best time. As you can see, we bought THOR at the best price we possibly could
have. Our system timed the low perfectly.
From there, we just had to wait 41 trading days for the first catalyst to hit. On December 9,
2019, pharmaceutical giant Sanofi announced that it was acquiring Synthorx.
13The stock skyrocketed 172% immediately following the news. That’s right – it jumped
172% in a single day. And because we timed our buy perfectly, we were already sitting on
big gains when that happened.
Ultimately, we booked profits of 432% in just over a month on the trade. That’s enough to
turn every $5,000 investment into $26,600. And we heard from subscribers who did even
better than that.
In fact, one subscriber told us he made $74,300 on THOR. This gentleman checked
his portfolio before breakfast on the day the acquisition was announced… and he was
surprised by a $74k windfall. That’s a good day.
These kinds of testimonials are immensely gratifying to me. The ability to have such a
positive impact on regular investors, who are typically ignored (or worse) by Wall Street, is
what drives me to do the work I do every day.
1410. Stemline Therapeutics (STML)
Founded: 2003
Headquarters: New York, NY
Website: https://stemline.com
This is Stemline Therapeutics (STML). The company is developing therapies for unmet
needs in the area of oncology.
Stemline Therapeutics went public in January 2013, and it ran up 37% in its first month of
trading. But then the stock dropped 22% over the next three months, creating a fantastic
buying opportunity.
From there, the stock traded steadily higher for six months until the first catalyst hit. The
FDA granted top therapy SL-401 “orphan drug” designation, which would enable the
therapy to progress more rapidly through the FDA’s clinical trial process.
That sent the stock soaring, and it ultimately traded up 321% from our entry point. That
would have turned every $5,000 investment into $21,050.
15Three Timed Stocks Set to Go Public progressing… and track the “smart money” that
This Year that is following.
There’s no doubt about it – this system can Keep in mind, these companies provide very
generate venture capital (VC)-like returns for little information to the public while they are
everyday investors in a short period of time. And private. But their VC backers know everything
it’s rather simple to follow. The system tells us there is to know… They are insiders. That’s
when to buy and when to sell. But this wasn’t an why it’s important to analyze each VC round. If
overnight project… the best VC firms are making larger and larger
investments in a private company, I know they’ve
In total, it took me five years to perfect my got something good.
“timed stocks” trading system. I poured
countless hours into research, analysis, and Doing this research on early stage companies
backtesting. In fact, I backtested this system on while they are still private is where part of my
every VC-backed IPO over the last decade. “edge” comes from. It is one of the reasons I
consistently beat the markets as well as the best
Today, I am going to fill you in on what gives hedge funds year after year.
my system its edge. I’m going to give you a peek
behind the curtain. By the time a company is preparing for its IPO,
I already have a great feel for the company and
It’s a simple thing, but it’s largely overlooked its potential. And with the trading system I have
throughout the rest of the investment research developed, we are able to time our entry points
industry. Here’s its competitive advantage… so that we get into these companies at prices
that are equal to – and sometimes even below –
Unlike Wall Street and most research services, I where the smart money got in.
don’t begin researching our portfolio companies
after they’ve gone public and started to pop up Plus, I already have an expectation of when
in stock screens and news feeds. I don’t use that each stock is going to soar. These stocks come
kind of common methodology in my research. with specific catalysts that are known to me in
After all, if we do the same thing others are advance. That’s why I call them “timed stocks.”
doing, we should expect the same results.
And that’s how my subscribers can earn such
Due to all of my early stage venture investing, outsized profits in a short period of time. With
I focus on companies at their earliest stage and this system, we get in ahead of major catalysts,
follow them as they raise additional capital. I well before these companies pop up on Wall
also spend my days reading scientific research Street’s radar… and we wait.
in order to understand the most important,
bleeding-edge developments in science and Then, when the catalyst hits, Wall Street takes
technology. I track the people and the companies notice and the stock explodes higher. Large
that are developing these technologies. amounts of institutional money tend to pile into
the stock, driving the price up dramatically.
I am always developing and monitoring my own Usually, this is our window to sell, take profits
lists of private companies that I believe have off the table, and reassess whether to buy back
incredible potential. I am following promising in on another pullback before yet another
companies throughout their entire life cycle. This catalyst hits.
enables me to get a feel for how each company is
16It’s something my team and I do for Today, I’m going to share three more “timed
months, sometimes years, before an actual stocks.” Two of these companies are private. But
recommendation. It’s how we constantly stay I expect they will IPO in the months ahead. The
ahead of traditional investment analysts. third stock recently held its IPO. I’m tracking this
company right now for a potential entry point.
171. Beam Therapeutics (BEAM)
Founded: 2017
Headquarters: Cambridge, MA
Website: https://beamtx.com
Beam Therapeutics is developing precision genetic therapies with the goal of curing all
human disease.
The company was founded by famed genetic editing scientist Feng Zhang. Zhang was the
scientist from the Broad Institute of MIT and Harvard who filed the first patent on CRISPR-
Cas9 technology. This was the patent that set the foundation for CRISPR genetic editing.
Simply put, this is one of the most promising biotechnology companies in the world.
What makes Beam Therapeutics so special is the work it is doing in DNA base editing. I’ll
explain it with a little background…
As we know, DNA is the building block of life. It is the hereditary material contained in
every cell of our body.
All strands of DNA consist of a sugar, a phosphate group, and a base pair. The sugar and
phosphate group are identical in every strand of a person’s DNA. They are the “backbone.”
The base pair determines what genetic information is expressed.
In DNA, there are only four bases that make up a pair. They are adenine (A), cytosine (C),
guanine (G), and thymine (T). Adenine always bonds with thymine to form a pair. And
guanine always bonds with cytosine to form a pair.
So the only naturally occurring base pairs in DNA are A-T and G-C. Here’s a visual:
Now, genetic mutations occur when one of these bases is transcribed incorrectly. For
example, when a sequence that should read “T-G-A-T-C” is transcribed as “T-A-A-T-C,”
that’s a genetic mutation, and it causes that gene to become dysfunctional. That, of course,
is what leads to many of the genetic diseases that have been uncurable up to this point.
18With its base editing technology, Beam Therapeutics can correct genetic mutations by
“rewriting” any single base pair. In other words, Beam can change any single base to any
other. In our simplistic example above, a G was mistakenly transcribed as an A. Beam’s
technology could go in and flip that A back to a G, correcting the mutation.
The ability to rewrite a single letter of the genome has never existed before. This is
bleeding-edge technology. And it has the potential to create lifelong cures for patients
suffering from serious genetic diseases.
Funding
Beam Therapeutics has raised $222 million in venture capital (VC) since its founding in
2017.
Among Beam’s VC backers were F-Prime Capital Partners, ARCH Venture Partners,
Inevitable Ventures, Digital Horizon Capital, Eight Roads, Omega Funds, Dreamers VC,
GV (Google Ventures), Osage University Partners, Altitude Life Science Ventures, Redmile
Group, and Cormorant Asset Management.
Outlook
Beam Therapeutics presented preclinical data for base editing approaches to both beta
thalassemia and sickle cell disease at the 61st Annual American Society of Hematology
(ASH) in Orlando, Florida, last December. The data was overwhelmingly positive and
could help support the filing of an investigational new drug application (IND) with the
FDA later this year. When approved, Beam Therapeutics would have the green light to
start human clinical trials for each of those diseases.
Beam is also developing therapies for leukemia, liver disease, and ocular disorders. Here’s
the company’s full base editing pipeline:
Click for larger version
This company is already making terrific progress. And Beam Therapeutics held its IPO
in February. It now trades under the ticker BEAM. So we will keep a close eye on Beam
Therapeutic. It could make for a very interesting trade in the near future.
192. eGenesis
Founded: 2014
Headquarters: Cambridge, MA
Website: www.egenesisbio.com
eGenesis is a company founded by famed Harvard geneticist and entrepreneur George
Church. Its goal is to grow human organs in animals for transplantation.
I know this might sound spectacular and even feel a bit uncomfortable, but it is critically
important work. There are more than 100,000 people in the U.S. alone waiting on an
organ transplant right now. And 20 of those people die every single day because they
didn’t receive an organ in time. There just aren’t enough human organs available for the
people who need them.
eGenesis wants to solve that problem.
The technical term for what eGenesis is doing is xenotransplantation. Xenotransplantation
is the transplantation of cells, tissue, or organs from one species to another. This has been
going on in the medical world for years now… to an extent.
For example, pig heart valves and cow cardiac tissue have been used for decades to repair
human heart valves. But we just haven’t been able to transplant full animal organs. The
human body rejects them.
That’s where eGenesis comes in. It is using CRISPR genetic editing technology to modify
the DNA of animal organs so the human body will accept them. CRISPR is able to
deactivate or remove the genes that cause humans to reject animal organs. And it can
insert human genes into the animal organs as well.
Ultimately, eGenesis’ goal is to create a biofactory of genetically modified animals with
organs that can be transplanted into humans on demand.
Funding
eGenesis has raised $138 million in venture capital since its founding in 2014. The
company is now valued at $175 million as it gets closer to going public.
Among eGenesis’ backers were Fresenius Medical Care Ventures, Wellington Partners,
Biomatics Capital, ARCH Venture Partners, Khosla Ventures, Alta Partners, Alexandria
Venture Investments, Heritage Provider Network, Berggruen Holdings North America,
Uprising, T1D Fund, and Fan Ventures.
20Outlook
eGenesis made a major announcement last December. Working on pig cells, it used CRISPR
to remove three pig genes and insert nine human genes in order to make the cells compatible
with humans. Then it created offspring to see if the edits “stuck”… And they did.
The pig offspring did not contain the three pig genes that were removed, and they have the
nine human genes that were inserted into the parent. This is incredible…
This basically means that eGenesis has created a special breed of pig whose organs can be
transplanted into humans at any time. This is the start of the biofactory, and it’s eventually
going to save hundreds of thousands of lives.
213. Arsenal Biosciences
Founded: 2019
Headquarters: San Francisco, CA
Website: www.arsenalbio.com
Arsenal Biosciences is a fascinating biotech company with a superstar management team.
The company plans to pair CRISPR genetic editing technology with synthetic biology to engi-
neer immune cell therapies that can kill cancer cells. The team refers to this approach as “pro-
grammable cell therapy.” It sees this as a groundbreaking new paradigm of cancer treatment.
Sean Parker founded Arsenal Bio… the same Sean Parker who founded Napster and was
an early investor in Facebook.
On the surface, this may sound like an odd match. But Parker is no stranger to the biotech
world. He was a supporter of the earliest CRISPR trials at the University of Pennsylvania.
In fact, the first human trial patient was dosed with a CRISPR therapy to cure cancer in
one of those trials.
Parker has also been a major donor to various cancer institutes. And he founded the
Parker Institute for Cancer Immunotherapy, which does great research.
So Parker has become an insider in the biotech space. And he has become familiar with its
top players. This has put him in a great position to launch his own biotech company. And
he has built a fantastic management team.
The chief executive officer (CEO) is Ken Drazan, M.D., who was formerly the president of a
company called Grail. Bill Gates backed Grail. Its focus is on liquid biopsies to detect cancer.
The chief technology officer (CTO) is Tarjei Mikkelsen, Ph.D., who was formerly a vice
president at 10X Genomics. I’ve been excited about 10X Genomics for years now. And the
company finally went public in 2019.
And the chief scientific officer (CSO) is Jane Grogan, Ph.D., who was formerly the head
of adaptive tumor immunity and principal scientist at Genentech, one of the successful
biotech companies in history.
Funding
Arsenal Biosciences raised $85 million in its Series A VC round in October 2019. This put
the company’s post-money valuation at $185 million.
Among Arsenal Bio’s backers were the Parker Institute for Cancer Immunotherapy, the
University of California and San Francisco, Kleiner Perkins, Osage Venture Partners,
Westlake Village BioPartners, and Euclidean Capital.
22Outlook
Having been founded last year, Arsenal Bio hit the ground running. Its approach to cancer
therapy is radically unique.
Arsenal Bio is moving beyond the current model of tumor-targeting strategies by encoding
biological “software” instructions to enable the body’s immune cells to target and destroy
cancer. In other words, it is programming cells to fight cancer.
As for its pipeline, the company has held it close to the vest up to this point. We can expect
to get more information on their progress later this year as the company gets closer to
going public.
Recent Accelerated Timed Stocks
I’m going to conclude this research report by sharing some recent “timed stocks” with
readers. Below, you’ll see a spreadsheet that outlines some recent winners our system
identified in backtesting.
Market Low Peak Market Low Peak
Ticker Return Ticker Return
Cap Date Date Cap Date Date
GTHR US PASG US
933.47k 3/3/2020 4/1/2020 3014.3% 1.06B 3/18/2020 6/4/2020 190.6%
Equity Equity
IMMB US ZNTL US
12.11k 1/7/2020 4/29/2020 2900.0% 1.64B 4/2/2020 5/29/2020 190.1%
Equity Equity
GNPX US CMRX US
102.51M 12/24/2019 2/25/2020 2490.4% 197.56M 3/18/2020 5/26/2020 185.8%
Equity Equity
BIEI US GBIM US
1.30M 1/24/2020 4/3/2020 2400.0% 460.13k 12/19/2019 3/24/2020 185.7%
Equity Equity
OBMP US ADVM US
1.75M 4/14/2020 6/5/2020 1983.3% 1.82B 3/12/2020 6/5/2020 184.0%
Equity Equity
IBIO US ARYX US
183.46M 12/2/2019 2/28/2020 1742.1% 122.14k 12/5/2019 6/5/2020 180.8%
Equity Equity
NSPX US BCEL US
34.15k 3/11/2020 4/1/2020 1452.6% 516.00M 12/2/2019 3/4/2020 170.6%
Equity Equity
NVAX US REPL US
2.76B 1/10/2020 5/18/2020 1349.4% 849.35M 3/23/2020 6/4/2020 164.2%
Equity Equity
BPSR US STSA US
47.77M 4/8/2020 5/21/2020 1285.9% 465.69M 12/11/2019 2/7/2020 164.1%
Equity Equity
CYDY US GTBP US
1.36B 12/2/2019 4/27/2020 1236.4% 14.14M 12/26/2019 5/28/2020 162.5%
Equity Equity
VXRT US ARPO US
179.53M 12/20/2019 4/27/2020 1182.0% 46.68M 3/18/2020 6/3/2020 162.5%
Equity Equity
PZRXQ US NWBO US
23.38k 1/29/2020 4/3/2020 1140.0% 251.07M 3/18/2020 5/26/2020 162.2%
Equity Equity
NNLX US TORC US
11.76M 1/6/2020 5/21/2020 1051.5% 79.45M 3/18/2020 5/26/2020 160.8%
Equity Equity
RCPIQ US FATE US
136.36k 3/24/2020 5/19/2020 1000.0% 2.19B 12/5/2019 5/22/2020 159.6%
Equity Equity
23Market Low Peak Market Low Peak
Ticker Return Ticker Return
Cap Date Date Cap Date Date
HGEN US CRTX US
532.80M 12/24/2019 6/3/2020 873.3% 1.22B 12/6/2019 2/14/2020 156.1%
Equity Equity
CAPR US TAUG US
61.05M 3/10/2020 4/29/2020 804.3% 3.26M 12/12/2019 4/8/2020 156.0%
Equity Equity
ABIO US PHAT US
13.63M 3/18/2020 5/28/2020 728.0% 1.36B 12/18/2019 6/5/2020 153.3%
Equity Equity
CBLI US CNST US
19.77M 12/26/2019 1/31/2020 642.0% 1.56B 3/18/2020 5/12/2020 153.0%
Equity Equity
INO US SRRK US
1.89B 12/5/2019 5/20/2020 577.7% 507.56M 12/5/2019 5/26/2020 152.2%
Equity Equity
TOCA US VIE US
31.33M 12/19/2019 3/6/2020 549.5% 2.72B 12/16/2019 5/22/2020 151.9%
Equity Equity
MGNX US OYST US
981.29M 3/18/2020 5/12/2020 534.3% 746.86M 12/11/2019 2/26/2020 151.6%
Equity Equity
ARCT US BHVN US
669.28M 3/13/2020 5/22/2020 525.9% 3.99B 3/16/2020 6/5/2020 147.7%
Equity Equity
PCNT US BCLI US
1.41M 12/16/2019 4/6/2020 525.0% 267.32M 12/19/2019 6/5/2020 146.1%
Equity Equity
MRSN US CALA US
1.37B 12/13/2019 5/29/2020 510.2% 374.06M 3/16/2020 4/15/2020 144.5%
Equity Equity
MCTC US GNCA US
6.02M 3/16/2020 5/28/2020 476.6% 67.45M 3/18/2020 5/26/2020 142.9%
Equity Equity
AXIM US BSTG US
57.80M 3/20/2020 5/26/2020 458.3% 23.00M 12/17/2019 3/3/2020 140.0%
Equity Equity
ALRN US SBBP US
45.43M 3/16/2020 5/29/2020 457.9% 190.95M 3/18/2020 5/26/2020 139.5%
Equity Equity
ALT US BDTX US
152.04M 2/26/2020 5/29/2020 449.1% 1.28B 3/18/2020 5/12/2020 137.3%
Equity Equity
TARA US PPMD US
288.54M 12/5/2019 6/2/2020 442.0% 554.01k 12/17/2019 5/13/2020 135.7%
Equity Equity
NK US SGNI US
545.74M 12/3/2019 5/27/2020 437.6% 1/3/2020 2/28/2020 135.3%
Equity Equity
NBY US SGMO US
24.32M 3/16/2020 3/19/2020 421.7% 1.55B 3/16/2020 6/1/2020 134.3%
Equity Equity
HTBX US PULM US
73.48M 2/27/2020 5/28/2020 421.1% 43.47M 12/20/2019 5/21/2020 133.5%
Equity Equity
DFFN US CVM US
53.99M 3/16/2020 5/15/2020 418.8% 534.40M 1/9/2020 4/30/2020 133.4%
Equity Equity
NVUS US GERN US
8.52M 3/18/2020 5/28/2020 403.5% 477.96M 3/18/2020 5/18/2020 132.2%
Equity Equity
VIR US CCXI US
3.92B 1/3/2020 2/27/2020 400.0% 3.71B 12/4/2019 5/27/2020 124.9%
Equity Equity
RCUS US KNSA US
1.66B 12/5/2019 5/20/2020 369.3% 1.26B 12/5/2019 5/11/2020 124.0%
Equity Equity
QLGN US RVMD US
9.47M 12/27/2019 5/12/2020 365.8% 1.94B 2/12/2020 5/7/2020 123.2%
Equity Equity
CRDF US RARE US
47.21M 3/18/2020 6/4/2020 359.6% 4.18B 3/16/2020 6/2/2020 122.2%
Equity Equity
MRNA US NGM US
22.63B 1/7/2020 5/18/2020 349.9% 1.41B 3/18/2020 5/11/2020 122.1%
Equity Equity
24Market Low Peak Market Low Peak
Ticker Return Ticker Return
Cap Date Date Cap Date Date
SVRA US ONTX US
126.81M 12/5/2019 12/30/2019 342.3% 79.56M 12/12/2019 2/10/2020 120.4%
Equity Equity
SRNE US TPTX US
863.92M 3/18/2020 5/15/2020 330.6% 2.65B 3/16/2020 6/2/2020 119.8%
Equity Equity
ATOS US CDXC US
30.94M 3/16/2020 6/5/2020 328.0% 282.18M 3/23/2020 5/7/2020 117.3%
Equity Equity
ONVO US ARQT US
87.10M 3/18/2020 5/13/2020 324.9% 1.20B 1/30/2020 3/23/2020 117.1%
Equity Equity
AFFY US XLRN US
1.17M 12/6/2019 1/22/2020 321.4% 4.93B 12/5/2019 5/11/2020 115.9%
Equity Equity
CFRX US ARDS US
136.73M 12/9/2019 1/14/2020 320.2% 60.23M 12/23/2019 5/8/2020 115.6%
Equity Equity
SURF US KROS US
133.11M 3/18/2020 5/21/2020 313.2% 641.33M 4/7/2020 6/3/2020 115.3%
Equity Equity
ARAV US ONCS US
193.78M 3/16/2020 5/11/2020 308.6% 49.83M 3/18/2020 5/26/2020 112.8%
Equity Equity
CTMX US VERU US
370.14M 3/16/2020 5/12/2020 305.5% 233.32M 12/2/2019 2/20/2020 111.1%
Equity Equity
NPHC US TWST US
2.81M 12/13/2019 2/20/2020 300.0% 1.65B 3/18/2020 5/18/2020 110.4%
Equity Equity
SNSS US DMTK US
46.66M 12/19/2019 3/2/2020 296.0% 209.75M 12/4/2019 3/3/2020 110.3%
Equity Equity
CWBR US IOVA US
118.72M 3/24/2020 5/5/2020 294.1% 4.60B 3/16/2020 5/22/2020 109.8%
Equity Equity
USRM US NTRP US
2.24M 1/2/2020 4/2/2020 287.9% 31.03M 3/18/2020 5/27/2020 106.1%
Equity Equity
ADRO US APRE US
184.31M 12/20/2019 2/20/2020 287.8% 568.69M 12/5/2019 12/27/2019 105.0%
Equity Equity
AVEO US CLDX US
118.35M 3/18/2020 5/26/2020 284.2% 58.33M 3/20/2020 6/3/2020 103.2%
Equity Equity
IMUN US DNLI US
6.63M 1/9/2020 5/6/2020 280.6% 2.74B 3/16/2020 6/3/2020 103.0%
Equity Equity
IMMU US NSTM US
7.09B 4/3/2020 5/20/2020 270.6% 1.70M 12/5/2019 3/11/2020 100.0%
Equity Equity
IGMS US FOLD US
1.83B 12/3/2019 3/4/2020 270.6% 3.32B 3/12/2020 6/2/2020 98.2%
Equity Equity
BIVI US KPTI US
41.33M 3/16/2020 6/5/2020 261.4% 1.30B 2/26/2020 3/2/2020 92.8%
Equity Equity
STML US LGND US
625.93M 3/18/2020 5/12/2020 258.2% 1.96B 3/16/2020 6/5/2020 92.5%
Equity Equity
OPGN US SRPT US
29.39M 12/31/2019 3/16/2020 257.5% 11.54B 3/18/2020 5/27/2020 90.8%
Equity Equity
VIRA US UBX US
24.94k 3/18/2020 6/5/2020 252.4% 394.62M 3/16/2020 6/2/2020 89.8%
Equity Equity
BCRX US EXEL US
735.59M 3/18/2020 5/20/2020 250.6% 6.86B 3/16/2020 5/11/2020 89.6%
Equity Equity
VSTM US REGN US
305.56M 12/18/2019 4/22/2020 250.0% 61.12B 1/30/2020 6/2/2020 83.7%
Equity Equity
DVAX US HALO US
631.53M 3/16/2020 6/1/2020 248.9% 3.21B 3/18/2020 5/11/2020 78.6%
Equity Equity
25Market Low Peak Market Low Peak
Ticker Return Ticker Return
Cap Date Date Cap Date Date
ATHX US OCX US
546.20M 12/18/2019 4/1/2020 243.1% 176.11M 12/4/2019 1/17/2020 73.6%
Equity Equity
IPIX US SGEN US
45.95M 12/26/2019 5/26/2020 241.6% 25.69B 3/16/2020 5/5/2020 72.8%
Equity Equity
CBAY US ATNM US
263.13M 3/18/2020 5/13/2020 240.0% 91.00M 3/18/2020 6/5/2020 71.4%
Equity Equity
BLAB US MTEM US
44.52k 1/6/2020 3/10/2020 233.3% 651.20M 12/13/2019 3/4/2020 70.8%
Equity Equity
LQDA US FRX CN
214.49M 12/19/2019 6/2/2020 230.0% 291.34M 3/18/2020 6/5/2020 66.3%
Equity Equity
OVID US ACAD US
289.65M 3/18/2020 5/26/2020 229.6% 7.11B 3/16/2020 5/20/2020 66.0%
Equity Equity
BIOC US GH US
62.89M 12/18/2019 2/28/2020 227.7% 8.18B 3/16/2020 5/15/2020 65.1%
Equity Equity
APLT US INCY US
923.13M 12/2/2019 2/5/2020 221.0% 20.33B 3/23/2020 4/24/2020 63.8%
Equity Equity
VCEX US MXCT LN
337.14k 3/26/2020 6/3/2020 218.6% 139.77M 12/2/2019 6/4/2020 61.5%
Equity Equity
SNDX US PDLI US
623.72M 1/29/2020 5/15/2020 215.5% 388.10M 3/20/2020 6/5/2020 58.8%
Equity Equity
CUE US ALXN US
695.31M 3/18/2020 6/2/2020 212.0% 25.44B 3/16/2020 5/29/2020 58.7%
Equity Equity
SELB US ANAB US
317.59M 12/18/2019 2/7/2020 209.6% 530.27M 3/23/2020 6/2/2020 58.7%
Equity Equity
IMUX US UTHR US
166.57M 3/16/2020 6/5/2020 208.5% 5.44B 3/18/2020 6/3/2020 58.3%
Equity Equity
LVGO US ALNY US
5.60B 3/16/2020 6/3/2020 206.4% 14.65B 3/12/2020 4/24/2020 56.4%
Equity Equity
IMVTU US BMRN US
1.96B 12/3/2019 6/3/2020 202.7% 19.13B 3/23/2020 6/3/2020 55.8%
Equity Equity
GHSI US AMHV US
42.38M 12/11/2019 5/22/2020 202.4% 718.59k 12/5/2019 3/30/2020 54.6%
Equity Equity
ORGS US SNBP US
168.71M 12/9/2019 6/3/2020 201.5% 31.83M 12/19/2019 3/2/2020 48.6%
Equity Equity
BGES US PLRX US
2.08M 3/20/2020 5/11/2020 200.0% 760.98M 6/2/2020 6/4/2020 46.0%
Equity Equity
AVXT US VRTX US
356.51k 12/23/2019 3/31/2020 200.0% 68.89B 3/16/2020 5/15/2020 44.5%
Equity Equity
TBIO US GILD US
935.45M 2/3/2020 5/26/2020 199.9% 96.27B 1/21/2020 4/30/2020 35.5%
Equity Equity
KZR US AMGN US
262.66M 12/2/2019 6/4/2020 199.2% 132.75B 3/12/2020 5/11/2020 33.2%
Equity Equity
YMAB US AMTI US
1.71B 3/18/2020 6/5/2020 199.1% 582.56M 6/4/2020 6/5/2020 28.4%
Equity Equity
ALLO US BIIB US
5.91B 3/18/2020 5/22/2020 196.6% 50.05B 1/31/2020 4/17/2020 27.4%
Equity Equity
TRVN US
140.41M 4/3/2020 5/26/2020 194.7%
Equity
26How to Become a Timed Stock Trader
Now, the trading window for these stocks have come and gone. But there are dozens
more on my radar. Each and every one of them has the potential to deliver explosive,
life-changing gains. And if you’d like to become a timed stock trader, then here’s what you
need to do today.
Mark this date on your calendar: July 15 at 8 p.m. ET. On that day, I’ll be hosting
the Timed Stocks Accelerated Summit. It’s a one-of-a-kind investing event where I’ll show
you the power of timed stocks and how you can add these trades to your portfolio right away.
It all goes down on July 15 at 8 p.m. ET. I hope to see you there.
JEFF BROWN’S TIMED STOCKS ACCELERATED SUMMIT
July 15 at 8 p.m. ET
“Thank you for the GREAT call on [your new timed stock]! I sold
my positions in the pre-market action this morning. That
banked me a profit of $74,300 before breakfast!”
– Don B.
To contact us, call toll free Domestic/International: 1-800-681-1765, Mon-Fri: 9am-5pm ET or email services@bonnerandpartners.com.
© 2020 Bonner & Partners, LLC. 55 NE 5th Ave., Delray Beach, FL 33483. All rights reserved. Any reproduction, copying, or redistribution, in whole or in part, is prohibited
without written permission from the publisher.
Information contained herein is obtained from sources believed to be reliable, but its accuracy cannot be guaranteed. It is not designed to meet your personal situation—we
are not financial advisors nor do we give personalized advice. The opinions expressed herein are those of the publisher and are subject to change without notice. It may
become outdated and there is no obligation to update any such information.
Recommendations in Bonner & Partners publications should be made only after consulting with your advisor and only after reviewing the prospectus or financial statements
of the company in question. You shouldn’t make any decision based solely on what you read here.
Bonner & Partners writers and publications do not take compensation in any form for covering those securities or commodities.
Bonner & Partners expressly forbids its writers from owning or having an interest in any security that they recommend to their readers. Furthermore, all other employees and
agents of Bonner & Partners and its affiliate companies must wait 24 hours before following an initial recommendation published on the Internet, or 72 hours after a printed
publication is mailed.
27You can also read
